Carotuximab, identified as TRC105 and DE-122, represents a novel antibody-drug conjugate construct currently being studied for combating various malignant diseases. This specific molecule binds to a specific antigen, https://sidneyyqjo062586.wikiexpression.com/6564215/carotuximab_trc105_de_122_a_deep_dive